{"url_path":"/sec/asth/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1083446/0001193125-26-213157-index.html","accession_number":"0001193125-26-213157","cik":"0001083446","ticker":"ASTH","issuer_name":"Astrana Health, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1083446/0001193125-26-213157-index.html","primary_entity_key":"0001083446","primary_entity_name":"Astrana Health, Inc."},"word_count":348,"has_tables":true,"body_markdown":"ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS\n\nIn December 2022, Astrana’s Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $50.0 million of its shares of common stock. In February 2026, the Board of Directors increased the total authorization under the share repurchase program to $100.0 million of its shares of common stock, including the $35.9 million that remained available under the previously announced stock repurchase program. Repurchases may be made through a variety of methods, which could include open market purchases, accelerated share repurchase transactions, negotiated block transactions, 10b5-1 plans, other transactions that may be structured through investment banking institutions or privately negotiated, or a combination of the foregoing. This share repurchase program has no expiration date. The Board may suspend, modify, or discontinue the repurchase program at any time. This repurchase program does not obligate the Company to make additional repurchases at any specific time or in any specific situation. During the three months ended March 31, 2026, 124,747 shares were repurchased under the Company’s share repurchase program. As of March 31, 2026, $83.1 million remained available under the repurchase program.\n\nThe following table provides information about purchases made by the Company of shares of the Company’s common stock during the three months ended March 31, 2026.\n\nPeriod\n\n \n\nTotal Number\nof Shares\nPurchased (1)\n\n \n\n \n\nAverage Price\nPaid Per\nShare\n\n \n\n \n\nTotal Number of\nShares\nPurchased as\nPart of Publicly\nAnnounced Plans\nor Programs\n\n \n\n \n\nApproximate Dollar\nValue of Shares That\nMay Yet Be\nPurchased Under the\nPlans or Programs\n(in thousands)\n\n \n\nJanuary 1, 2026 to January 31, 2026\n\n \n\n \n\n141,882\n\n \n\n \n\n$\n\n22.96\n\n \n\n \n\n \n\n123,566\n\n \n\n \n\n$\n\n33,132\n\n \n\nFebruary 1, 2026 to February 28, 2026\n\n \n\n \n\n1,292\n\n \n\n \n\n$\n\n22.28\n\n \n\n \n\n \n\n1,181\n\n \n\n \n\n$\n\n83,105\n\n \n\nMarch 1, 2026 to March 31, 2026\n\n \n\n \n\n20,742\n\n \n\n \n\n$\n\n24.92\n\n \n\n \n\n \n\n—\n\n \n\n \n\n$\n\n83,105\n\n \n\nTotal\n\n \n\n \n\n163,916\n\n \n\n \n\n$\n\n23.21\n\n \n\n \n\n \n\n124,747\n\n \n\n \n\n \n\n \n\n(1)\nIncludes 39,169 shares repurchased to satisfy tax withholding obligations due upon the vesting of restricted stock awards held by certain employees. We did not pay cash to repurchase these shares, nor were these repurchases part of a publicly announced plan or program."}